Characterization of a region upstream of exon I.1 of the human CYP19 (aromatase) gene that mediates regulation by retinoids in human choriocarcinoma cells.
Sun T., Zhao Y., Mangelsdorf DJ., Simpson ER.
Laboratory Study, published in Endocrinology (1998) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Endocrinology (1998)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 9528950
- DOI
- 10.1210/endo.139.4.5959
Abstract (original English)
The biosynthesis of estrogens is catalyzed by aromatase P450 (P450arom), the product of the CYP19 gene. The tissue-specific expression of the CYP19 gene is regulated by means of tissue-specific promoters through the use of alternative splicing mechanisms. Thus, transcripts containing various 5'-untranslated termini are present in ovary, brain, adipose stromal cells, and placenta. Sequence corresponding to untranslated exon I.1 is present uniquely in 5'-termini of transcripts expressed in human placenta and choriocarcinoma cells, as a consequence of expression driven by a distal promoter, I.1. The goal of the present study was the identification of regulatory elements in this promoter region. Various deletion mutations of the upstream flanking region of exon I.1 were constructed using the PCR or restriction enzyme digestion. The genomic fragments were fused upstream of the luciferase reporter gene. These constructs were transfected into human choriocarcinoma (JEG3) cells. The longest construct employed, -924/+10 bp, expressed the highest luciferase reporter gene activity. The -64/+10 bp and -125/+10 bp constructs showed no reporter gene expression. Transfection of the -201/+10 bp construct resulted in reporter gene expression, but at a lower level than that of the -924/+10 bp construct, and this expression was induced by serum as well as by LG69 and TTNPB, ligands specific for R
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.